ClinicalTrials.gg
Not yet recruitingNCT06692842Updated Jan 7, 2026

Interactive Technological Intervention to Improve Mental Health Symptoms in Primary Health Care

An interventional study of CONEMO App in Depression, Anxiety and Insomnia, sponsored by University of Sao Paulo General Hospital. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12,400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Depression with a site in Brazil — 19 open to participants now, 24 under way, 3 of them phase 3. Depression · Brazil.

Planned enrollment
Largest of 91
12,400 · median 80
Started
2026
with 7 others
No phase
62 of 100
13 open now
Primary completion
2026-12
later than 13 of 23 live
Registered
84th of 100
by date
Lead sponsor
9 of 100
University of Sao Paulo General Hospital

Among the 100 studies in Depression with a site in Brazil, this one has the largest planned enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2026, is one of 62 with no phase, reaches primary completion later than 13 of the 23 other live ones, and was the 84th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

19 of the 100 studies in Depression with a site in Brazil are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Depression with a site in Brazil, or all of them as a file.
02

Study summary

This study aims to implement and evaluate a technological intervention called CONEMO to treat depressive symptoms, anxiety, and insomnia in adults who use primary health care services. The effectiveness of this intervention has already been proven in previous research, specifically for depressive symptoms. Implementation will occur in 28 basic health units in the municipalities of Indiatuba and Jaguariúna in the interior of São Paulo.

All eligible residents of the cities will be invited to participate.

Read the detailed description

A type III hybrid implementation and effectiveness study, with a mixed-method explanatory sequential design consisting of two distinct stages: the first quantitative, followed by qualitative. The method is indicated when the researcher wishes to use qualitative data to help interpret and explain the initial quantitative findings and deepen them. The elements of both methods are analyzed separately and then merged, looking for convergences, divergences, contradictions, or relationships between the two databases.

The qualitative data will help to interpret, explain and deepen the quantitative findings. The guidelines of the Consolidated Criteria for Reporting Qualitative Research (COREQ) will be followed, a 32-item instrument that guides the conduct of the interview and analysis of qualitative data, also validated in Portuguese in Brazil.

Study site The study will be carried out in 28 Basic Health Units (UBS) in two municipalities in the interior of São Paulo, Indaiatuba and Jaguariúna, located approximately 100 km from the capital São Paulo, in the state of São Paulo, Brazil.

Study population - stakeholder groups Patients/service users - user category Our study population will be made up of adult individuals (18 years or older) who live in the municipality of Indaiatuba or Jaguariúna and attend the UBS and who show significant symptoms of depression, anxiety or insomnia.

Health professionals, service managers and local managers - professional categories Adults (18 years or older) from the groups of interest will also participate in the study: health professionals from the UBS in the municipalities of Jaguariúna and Indaiatuba, service managers, health department managers, or primary care and mental health coordinators. We consider these individuals to be the main stakeholders, in addition to the users and main participants in the research, in the unfolding of the CONEMO intervention implementation study.

Study population

User participants - quantitative study:

All individuals screened at the cities' UBSs with positive symptoms for insomnia, anxiety or depression.

Participants - users, health professionals and managers - barriers and facilitators - qualitative study The focus groups in this study will be divided into categories of participants selected from each UBS involved. The categories of participation will be users, technical health professionals, senior health professionals and the manager of each participating unit. Simple randomization will be carried out to select one participant from each category among users and health professionals. With regard to managers, the invitation will be extended to all managers of the participating health units. These focus groups will be conducted separately for each category of participants at the end of three months from the start of the study. It is important to note that the users included in the focus groups may be at different stages of using the application. Specific guiding scripts will be used to collect the qualitative data, which will be drawn up after analyzing the quantitative data.

Research Steering Committee - CGP This committee plays a crucial role in monitoring and evaluating the outcomes of the implementation of interventions and policies. Composed of a multidisciplinary team, including academic researchers, local managers, and service workers, the committee facilitates the active participation of all stakeholders in the research process. Its main objective is to ensure that contextual elements are taken into account and that real conditions are understood and worked on. The committee meets regularly to discuss the research progress, evaluate the strategies' implementation and provide constructive feedback. This participatory and collaborative approach helps to identify and overcome possible challenges in implementation, thus promoting the effectiveness and sustainability of the mental health policies implemented. The CGP will also include users of municipal health services.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Look for consultation in basic health units due to Major Depressive Disorder, Insomnia and/or Generalized Anxiety Disorder, or who receive home visits for the same reason.
  • Score >= 10 on the PHQ-9 Scale for Depression; and/or >= 11 on the IGI Scale for Insomnia; and/or >= 10 on the GAD-7 Scale for Anxiety.
  • Be able to read the app\'s instructions via a tablet or smartphone screen.

Exclusion criteria

Exclusion Criteria:

  • Individuals considered severe on the Suicide Risk Assessment Protocol-SRAP (suicidal imminence)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12,400 participants (estimated)

Study arms

  • Experimental
    CONEMO

    CONEMO is a low-intensity psychoeducational program which is made available to users via smartphones compatible with Android or iOS systems. At the same time, the designed healthcare professional use a tablet to monitor user adherence to the intervention. CONEMO comprise seven weekly modules, totally self-guides.

    Device: CONEMO App

Interventions

  • DeviceCONEMO App

    The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who have 'recovered' from depressive symptoms (PHQ-9 < 10)

    Patient Health Questionnaire-9 (PHQ-9) is a questionnaire to access the severity of participants' depressive symptoms. The PHQ-9 score varies according to the severity of the symptoms and is classified as follows: no depression (0 to 4), mild symptoms (5 to 9), moderate symptoms (10 to 14), moderately severe symptoms (15 to 19) and severe symptoms (20 to 27). A cut-off point of 10 is suggested to indicate the presence of significant depressive symptoms.

    Time frame: 3 months

  2. Proportion of participants who have 'recovered' from anxiety (GAD-7< 10)

    General Anxiety Disorder-7 (GAD-7) scale, which measures common symptoms associated with generalized anxiety disorder in the last two weeks. Each of the scale's seven items ranges from 0 ('not at all') to 3 ('almost every day'), resulting in a total score ranging from 0 to 21. A suggested cut-off point of more than 10 points indicates the presence of anxiety.

    Time frame: 3 months

  3. Proportion of participants who have 'recovered' from insomnia (IGI<8)

    Insomnia Severity Index (IGI) is a retrospective instrument that assesses the last month and is made up of seven items that explore various aspects of sleep, including difficulties initiating or maintaining sleep, early morning awakening, satisfaction with sleep, daytime impairment, perception of sleep problems by other people, and concern about sleep problems. Respondents use a Likert scale ranging from 0 (no severity) to 4 (high severity), resulting in a total score ranging from 0 to 28. This score is classified as follows: no insomnia (0 to 7), mild insomnia (8 to 14), moderate insomnia (15 to 21) and severe insomnia (22 to 28

    Time frame: 3 months

Secondary outcomes

  1. Social Support Assessment:

    The participant's relationships with other people, i.e. whether they have a support network, will be explored throught a questionnaire

    Time frame: 3 months and 6 months

  2. Quality of Life

    The level 3 version of the 5-item EUROQol questionnaire (EQ 5D-3L), which covers five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with three levels of severity, will be used to access changes in quality of life.

    Time frame: 3 months and 6 months

  3. Daily Activity Level:

    Through the short form of the Behavioral Activation Scale for Depression (BADS). The BADS is a 9-item scale that measures the frequency of activation and avoidance behaviors that are hypothetically fundamental to the mechanisms of depression. This instrument will only be applied to participants in the depression journey.

    Time frame: 3 months and 6 months

07

Study locations

1 site
  • Basic Health System
    Indaiatuba and Jaguariúna, São Paulo, Brazil
    • Paulo Rossi Menezes, PhD · Contactpmenezes@usp.br · (11) 2661-7585
    • Alice Xavier, PhD · Contactalicexavier@gmail.com · +55 51 99266 4409
    • Alice Castro Menezes Xavier, Ph.D. · Sub investigator
    • Renatha El-Rafihi Ferreira, Ph.D. · Sub investigator
    • Paulo Rossi Menezes, Ph.D. · Principal investigator
    • Heloisa Garcia Claro Fernandes, Ph.D. · Sub investigator
    • Anita Castro Menezes Xavier, M.Sc. · Sub investigator
    • Aline G. de Lima Baquete, R.N. · Sub investigator
    • Beatriz H. de Souza Atti, B.Sc · Sub investigator
    • Léo Paulos-Guarnieri, B.Sc. · Sub investigator
    • Beatriz Almeida Silva de Thomaz, BMsc. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be shared on the OSF platform after the study is completed, upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After study completion and publication of the results

Access criteria: Upon request from others researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 18, 2024
StartEst.
Jan 5, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06692842
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Jan 5, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 7, 2026

Study contacts

Paulo Rossi Menezes, Ph.D.
Contact
pmenezes@usp.br
5530617444
Alice C. M. Xavier, Ph.D.
Contact
alicexavier@gmail.com
5592664409

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion